Mebendazole
Mebendazole. Benzimidazole anthelmintic — same β-tubulin mechanism as albendazole. First-line for pinworm + roundworm + hookworm + whipworm.… Oral half-life 1.1 h.
Benzimidazole anthelmintic — same β-tubulin mechanism as albendazole. First-line for pinworm + roundworm + hookworm + whipworm. Minimally absorbed, so primarily a luminal-effect drug; few systemic side effects at standard doses.
PK: the citation is genuinely good — a human crossover with both routes — but the record misread it twice. F 0.1 against a STATED 22%, and a half-life of 0.93 h that is the ORAL arm, which is shorter than the same paper intravenous value of 1.12 h and therefore cannot be a disposition half-life; the gap is noise in a five-subject tracer study. The intravenous figure is now stored. BOTH ARE TRACER-DOSE VALUES IN SOLUTION and do not describe therapeutic dosing: at 10 mg/kg in tablets the half-life runs 2.8 to 9.0 h. The paper also explains its own bioavailability — at tracer dose absorption is "almost complete" and the 22% loss is entirely first-pass — so the figure does not transfer to tablets, where absorption is dissolution-limited and fat-dependent. V 90 L dropped as unsourced. THE EFFECT IS DECOUPLED FOR THE DRUG MAIN USE: against intestinal helminths mebendazole acts in the GUT LUMEN, so the plasma curve measures the fraction that escaped the site of action, and a systemic model addresses the wrong compartment for most prescriptions.
Pharmacokinetics
- Oral — t½ 1.1 h · F 22%
Sources: PMID:3978023, PMID:7094986